Literature DB >> 8624816

Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection.

L Soong1, J C Xu, I S Grewal, P Kima, J Sun, B J Longley, N H Ruddle, D McMahon-Pratt, R A Flavell.   

Abstract

To study the role of CD40 ligand (CD40L) in the host immune responses against intracellular pathogens, we infected CD40L knockout (CD40L-/-) mice with Leishmania amazonensis. Although wild-type mice were susceptible to infection and developed progressive ulcerative lesions, tissue parasite burdens in CD40L-/- mice were significantly higher. This heightened susceptibility to infection was associated with an impaired T cell and macrophage activation and altered inflammatory response, as reflected by low levels of IFN gamma, lymphotoxin-tumor necrosis factor (LT-TNF), and nitric oxide (NO) production. Furthermore, CD40L-/- mice failed to generate a protective immune response after immunization. These results indicate an essential role of cognate CD40-CD40L interactions in the generation of cellular immune responses against an intracellular parasite.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8624816     DOI: 10.1016/s1074-7613(00)80434-3

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  93 in total

1.  The Abl and Arg kinases mediate distinct modes of phagocytosis and are required for maximal Leishmania infection.

Authors:  Dawn M Wetzel; Diane McMahon-Pratt; Anthony J Koleske
Journal:  Mol Cell Biol       Date:  2012-06-04       Impact factor: 4.272

2.  Absence of CD40-CD40 ligand interactions in X-linked hyper-IgM syndrome does not affect differentiation of T helper cell subsets.

Authors:  H Uronen; R E Callard
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, previously revealed in genome-wide association studies.

Authors:  Naoya Inoue; Mikio Watanabe; Hiroya Yamada; Kazuya Takemura; Fumiaki Hayashi; Noriko Yamakawa; Maiko Akahane; Yu Shimizuishi; Yoh Hidaka; Yoshinori Iwatani
Journal:  J Clin Immunol       Date:  2012-06-17       Impact factor: 8.317

4.  Murine AIDS requires CD154/CD40L expression by the CD4 T cells that mediate retrovirus-induced disease: Is CD4 T cell receptor ligation needed?

Authors:  Wen Li; William R Green
Journal:  Virology       Date:  2006-11-17       Impact factor: 3.616

5.  Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions.

Authors:  N Chirmule; S E Raper; L Burkly; D Thomas; J Tazelaar; J V Hughes; J M Wilson
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  CD40 induces macrophage anti-Toxoplasma gondii activity by triggering autophagy-dependent fusion of pathogen-containing vacuoles and lysosomes.

Authors:  Rosa M Andrade; Matthew Wessendarp; Marc-Jan Gubbels; Boris Striepen; Carlos S Subauste
Journal:  J Clin Invest       Date:  2006-09       Impact factor: 14.808

Review 7.  Sex hormones and modulation of immunity against leishmaniasis.

Authors:  Heidi Snider; Claudio Lezama-Davila; James Alexander; Abhay R Satoskar
Journal:  Neuroimmunomodulation       Date:  2009-02-11       Impact factor: 2.492

8.  The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection.

Authors:  Dawn M Wetzel; Emma L Rhodes; Shaoguang Li; Diane McMahon-Pratt; Anthony J Koleske
Journal:  J Cell Sci       Date:  2016-06-29       Impact factor: 5.285

Review 9.  CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes.

Authors:  A Bhushan; L R Covey
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

10.  Overexpression of methyl-CpG binding protein 2 impairs T(H)1 responses.

Authors:  Tianshu Yang; Melissa B Ramocki; Jeffrey L Neul; Wen Lu; Luz Roberts; John Knight; Christopher S Ward; Huda Y Zoghbi; Farrah Kheradmand; David B Corry
Journal:  Sci Transl Med       Date:  2012-12-05       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.